MK 0686Alternative Names: MK-0686
Latest Information Update: 18 Mar 2010
At a glance
- Originator Merck & Co
- Class Analgesics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Postherpetic neuralgia
Most Recent Events
- 26 Jun 2006 Phase-II clinical trials in Postherpetic neuralgia in USA (unspecified route)